- ImmunoGen (NASDAQ:IMGN) Q3 results: Revenues: $8.5M (+10.4%); Operating Loss: ($31.1M) (+19.8%); Net Loss: ($56.7M) (-26.8%); Loss Per Share: ($0.61) (-19.6%); Quick Assets: $194.9M (+21.8%).
- 2017 Guidance: Revenues: $115M - 120M (unch); Operating Expenses: $170M - 175M from $175M - 180M; Cash and cash equivalents: $260M - 265M from $90M - 95M.
- Shares are down 1% premarket on modest volume.